Selected research
Industry Growth & Trends
Global G-CSF and G-CSF Biosimilars Industry Growth and Trends Forecast to 2032
Market perspective
The global G-CSF and G-CSF Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for G-CSF and G-CSF Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for G-CSF and G-CSF Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for G-CSF and G-CSF Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of G-CSF and G-CSF Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer, GlaxoSmithKline, Bayer and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global G-CSF and G-CSF Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The G-CSF and G-CSF Biosimilars market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global G-CSF and G-CSF Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to G-CSF and G-CSF Biosimilars.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global G-CSF and G-CSF Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
G-CSF and G-CSF Biosimilars Market by Company
Sanofi
Johnson & Johnson
Novartis
Merck & Co.
Roche
Pfizer
GlaxoSmithKline
Bayer
Amgen
AbbVie
AstraZeneca
Gilead Science
G-CSF and G-CSF Biosimilars Segment by Type
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
Blood Disorders
Oncology Diseases
G-CSF and G-CSF Biosimilars Segment by Application
Insulin
Human Growth Hormone
Interferon
Monoclonal Antibodies
Erythropoietin
G-CSF and G-CSF Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global G-CSF and G-CSF Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of G-CSF and G-CSF Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of G-CSF and G-CSF Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of G-CSF and G-CSF Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of G-CSF and G-CSF Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chronic And Autoimmune Diseases
- Growth Hormone Deficiencies
- Blood Disorders
- Oncology Diseases
Applications
- Insulin
- Human Growth Hormone
- Interferon
- Monoclonal Antibodies
- Erythropoietin
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck & Co.
- Roche
- Pfizer
- GlaxoSmithKline
- Bayer
- Amgen
- AbbVie
- AstraZeneca
- Gilead Science
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global G-CSF and G-CSF Biosimilars Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global G-CSF and G-CSF Biosimilars Sales Estimates and Forecasts (2021-2032)
- 1.3 G-CSF and G-CSF Biosimilars Market by Type
- 1.3.1 Chronic And Autoimmune Diseases
- 1.3.2 Growth Hormone Deficiencies
- 1.3.3 Blood Disorders
- 1.3.4 Oncology Diseases
- 1.4 Global G-CSF and G-CSF Biosimilars Market Size by Type
- 1.4.1 Global G-CSF and G-CSF Biosimilars Market Size Overview by Type (2021-2032)
- 1.4.2 Global G-CSF and G-CSF Biosimilars Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global G-CSF and G-CSF Biosimilars Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America G-CSF and G-CSF Biosimilars Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe G-CSF and G-CSF Biosimilars Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific G-CSF and G-CSF Biosimilars Sales Breakdown by Type (2021-2026)
- 1.5.4 South America G-CSF and G-CSF Biosimilars Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa G-CSF and G-CSF Biosimilars Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 G-CSF and G-CSF Biosimilars Industry Trends
- 2.2 G-CSF and G-CSF Biosimilars Industry Drivers
- 2.3 G-CSF and G-CSF Biosimilars Industry Opportunities and Challenges
- 2.4 G-CSF and G-CSF Biosimilars Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by G-CSF and G-CSF Biosimilars Revenue (2021-2026)
- 3.2 Global Top Players by G-CSF and G-CSF Biosimilars Sales (2021-2026)
- 3.3 Global Top Players by G-CSF and G-CSF Biosimilars Price (2021-2026)
- 3.4 Global G-CSF and G-CSF Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global G-CSF and G-CSF Biosimilars Major Company Production Sites & Headquarters
- 3.6 Global G-CSF and G-CSF Biosimilars Company, Product Type & Application
- 3.7 Global G-CSF and G-CSF Biosimilars Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global G-CSF and G-CSF Biosimilars Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 G-CSF and G-CSF Biosimilars Players Market Share by Revenue in 2025
- 3.8.3 2025 G-CSF and G-CSF Biosimilars Tier 1, Tier 2, and Tier 3
4 G-CSF and G-CSF Biosimilars Regional Status and Outlook
- 4.1 Global G-CSF and G-CSF Biosimilars Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global G-CSF and G-CSF Biosimilars Historic Market Size by Region
- 4.2.1 Global G-CSF and G-CSF Biosimilars Sales in Volume by Region (2021-2026)
- 4.2.2 Global G-CSF and G-CSF Biosimilars Sales in Value by Region (2021-2026)
- 4.2.3 Global G-CSF and G-CSF Biosimilars Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global G-CSF and G-CSF Biosimilars Forecasted Market Size by Region
- 4.3.1 Global G-CSF and G-CSF Biosimilars Sales in Volume by Region (2027-2032)
- 4.3.2 Global G-CSF and G-CSF Biosimilars Sales in Value by Region (2027-2032)
- 4.3.3 Global G-CSF and G-CSF Biosimilars Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 G-CSF and G-CSF Biosimilars by Application
- 5.1 G-CSF and G-CSF Biosimilars Market by Application
- 5.1.1 Insulin
- 5.1.2 Human Growth Hormone
- 5.1.3 Interferon
- 5.1.4 Monoclonal Antibodies
- 5.1.5 Erythropoietin
- 5.2 Global G-CSF and G-CSF Biosimilars Market Size by Application
- 5.2.1 Global G-CSF and G-CSF Biosimilars Market Size Overview by Application (2021-2032)
- 5.2.2 Global G-CSF and G-CSF Biosimilars Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global G-CSF and G-CSF Biosimilars Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America G-CSF and G-CSF Biosimilars Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe G-CSF and G-CSF Biosimilars Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific G-CSF and G-CSF Biosimilars Sales Breakdown by Application (2021-2026)
- 5.3.4 South America G-CSF and G-CSF Biosimilars Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa G-CSF and G-CSF Biosimilars Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Company Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Sanofi G-CSF and G-CSF Biosimilars Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Johnson & Johnson G-CSF and G-CSF Biosimilars Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Novartis G-CSF and G-CSF Biosimilars Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Merck & Co.
- 6.4.1 Merck & Co. Company Information
- 6.4.2 Merck & Co. Business Overview
- 6.4.3 Merck & Co. G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Merck & Co. G-CSF and G-CSF Biosimilars Product Portfolio
- 6.4.5 Merck & Co. Recent Developments
- 6.5 Roche
- 6.5.1 Roche Company Information
- 6.5.2 Roche Business Overview
- 6.5.3 Roche G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Roche G-CSF and G-CSF Biosimilars Product Portfolio
- 6.5.5 Roche Recent Developments
- 6.6 Pfizer
- 6.6.1 Pfizer Company Information
- 6.6.2 Pfizer Business Overview
- 6.6.3 Pfizer G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Pfizer G-CSF and G-CSF Biosimilars Product Portfolio
- 6.6.5 Pfizer Recent Developments
- 6.7 GlaxoSmithKline
- 6.7.1 GlaxoSmithKline Company Information
- 6.7.2 GlaxoSmithKline Business Overview
- 6.7.3 GlaxoSmithKline G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 GlaxoSmithKline G-CSF and G-CSF Biosimilars Product Portfolio
- 6.7.5 GlaxoSmithKline Recent Developments
- 6.8 Bayer
- 6.8.1 Bayer Company Information
- 6.8.2 Bayer Business Overview
- 6.8.3 Bayer G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Bayer G-CSF and G-CSF Biosimilars Product Portfolio
- 6.8.5 Bayer Recent Developments
- 6.9 Amgen
- 6.9.1 Amgen Company Information
- 6.9.2 Amgen Business Overview
- 6.9.3 Amgen G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Amgen G-CSF and G-CSF Biosimilars Product Portfolio
- 6.9.5 Amgen Recent Developments
- 6.10 AbbVie
- 6.10.1 AbbVie Company Information
- 6.10.2 AbbVie Business Overview
- 6.10.3 AbbVie G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 AbbVie G-CSF and G-CSF Biosimilars Product Portfolio
- 6.10.5 AbbVie Recent Developments
- 6.11 AstraZeneca
- 6.11.1 AstraZeneca Company Information
- 6.11.2 AstraZeneca Business Overview
- 6.11.3 AstraZeneca G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 AstraZeneca G-CSF and G-CSF Biosimilars Product Portfolio
- 6.11.5 AstraZeneca Recent Developments
- 6.12 Gilead Science
- 6.12.1 Gilead Science Company Information
- 6.12.2 Gilead Science Business Overview
- 6.12.3 Gilead Science G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 Gilead Science G-CSF and G-CSF Biosimilars Product Portfolio
- 6.12.5 Gilead Science Recent Developments
7 North America by Country
- 7.1 North America G-CSF and G-CSF Biosimilars Sales by Country
- 7.1.1 North America G-CSF and G-CSF Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America G-CSF and G-CSF Biosimilars Sales by Country (2021-2026)
- 7.1.3 North America G-CSF and G-CSF Biosimilars Sales Forecast by Country (2027-2032)
- 7.2 North America G-CSF and G-CSF Biosimilars Market Size by Country
- 7.2.1 North America G-CSF and G-CSF Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America G-CSF and G-CSF Biosimilars Market Size by Country (2021-2026)
- 7.2.3 North America G-CSF and G-CSF Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe G-CSF and G-CSF Biosimilars Sales by Country
- 8.1.1 Europe G-CSF and G-CSF Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe G-CSF and G-CSF Biosimilars Sales by Country (2021-2026)
- 8.1.3 Europe G-CSF and G-CSF Biosimilars Sales Forecast by Country (2027-2032)
- 8.2 Europe G-CSF and G-CSF Biosimilars Market Size by Country
- 8.2.1 Europe G-CSF and G-CSF Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe G-CSF and G-CSF Biosimilars Market Size by Country (2021-2026)
- 8.2.3 Europe G-CSF and G-CSF Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific G-CSF and G-CSF Biosimilars Sales by Country
- 9.1.1 Asia-Pacific G-CSF and G-CSF Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific G-CSF and G-CSF Biosimilars Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific G-CSF and G-CSF Biosimilars Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific G-CSF and G-CSF Biosimilars Market Size by Country
- 9.2.1 Asia-Pacific G-CSF and G-CSF Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific G-CSF and G-CSF Biosimilars Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific G-CSF and G-CSF Biosimilars Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America G-CSF and G-CSF Biosimilars Sales by Country
- 10.1.1 South America G-CSF and G-CSF Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America G-CSF and G-CSF Biosimilars Sales by Country (2021-2026)
- 10.1.3 South America G-CSF and G-CSF Biosimilars Sales Forecast by Country (2027-2032)
- 10.2 South America G-CSF and G-CSF Biosimilars Market Size by Country
- 10.2.1 South America G-CSF and G-CSF Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America G-CSF and G-CSF Biosimilars Market Size by Country (2021-2026)
- 10.2.3 South America G-CSF and G-CSF Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa G-CSF and G-CSF Biosimilars Sales by Country
- 11.1.1 Middle East and Africa G-CSF and G-CSF Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa G-CSF and G-CSF Biosimilars Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa G-CSF and G-CSF Biosimilars Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa G-CSF and G-CSF Biosimilars Market Size by Country
- 11.2.1 Middle East and Africa G-CSF and G-CSF Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa G-CSF and G-CSF Biosimilars Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa G-CSF and G-CSF Biosimilars Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 G-CSF and G-CSF Biosimilars Value Chain Analysis
- 12.1.1 G-CSF and G-CSF Biosimilars Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 G-CSF and G-CSF Biosimilars Production Mode & Process
- 12.2 G-CSF and G-CSF Biosimilars Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 G-CSF and G-CSF Biosimilars Distributors
- 12.2.3 G-CSF and G-CSF Biosimilars Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst